The U.S. Trade Representative keeps India on the priority watch list and designates Vietnam as a Priority Foreign Country in the Special 301 process, citing concerns over intellectual property protection.

Enforcement gaps exist, including weak coordination, non-deterrent penalties, high piracy and counterfeiting, and backlogs in trademarks and examination quality.

The USTR plans to use enforcement tools to confront unfair trade practices and expects countries to address gaps in their IP systems.

India’s role in global drug pricing is pivotal, as it supplies about one-fifth of the world’s generic medicines, influencing affordability worldwide.

India argues that US pressure could undermine its generics industry and global access to affordable medicines, given generics often slash prices by 80–90%.

India defends its regime as WTO-compliant and resistant to TRIPS-plus measures that would expand data exclusivity and broaden patentability.

India frames its approach as balancing innovation with access, preventing evergreening, and citing court rulings and WTO compatibility in its favor.

Section 3(d) remains a core point of contention, designed to curb evergreening by requiring enhanced efficacy for certain new forms of known drugs to receive patent protection.

The Special 301 report is an administrative, non-binding instrument that can lead to negotiations or further action, but carries no immediate legal penalties for India.

Designation could shift economic and diplomatic dynamics, affecting US–India trade talks, tariffs, market access, regulatory reform, and investor sentiment in IP-heavy sectors.

US concerns include shortening patent pendency and addressing the restrictive application of Section 3(d) to pharmaceutical innovations.

The designation reflects enduring differences in IP policy between the US and India, especially in pharmaceuticals and digital sectors, shaping trade discussions.